Migraine is a primary headache disorder associated with a high socioeconomic burden. The first step in effective migraine management, following confirmation of the diagnosis, is patient education: the condition is carefully explained, to ensure that it is properly understood, and realistic expectations are set. The choice of acute treatment has changed over time as the available therapeutic options have increased.
economic impact of the disease is considerable. It is more prevalent in women than in men, and in the age range 30-50 years. 1, 2 The choice of acute treatment for migraine has changed over time as the available therapeutic options have increased. In the 1990s the triptans replaced butalbital, opioids and ergot derivatives for the treatment of moderate to severe migraine pain. Even though acute symptomatic therapy can be optimised, migraine remains a chronic and potentially progressive condition.
The Mechanisms of Migraine
The understanding of migraine pathogenesis is currently incomplete, but growing; multiple pathophysiological mechanisms in the peripheral and central nervous system seem to play a role. Interictal susceptibility, aura mechanisms, potential migraine generators and especially cascading molecular events underlying migraine-associated pain and related symptoms must all be taken into consideration in order to understand the medical treatment of migraine attacks. in view of this, inhibition of neuronal-satellite glial cell signalling has been postulated as a target mechanism for anti-migraine therapy. 5 Cortical spreading depression (CSD) is now generally accepted as the mechanism underlying migraine aura, even though the way in which aura activates headache remains to be established. 6 Migraine without aura is thought to be due either to CSD invading 'silent' brain areas or to activation of subcortical centres.
CSD increases adenosine 5'-triphosphate and other pro-inflammatory molecules in the cerebrospinal fluid. 7, 8 It releases nitric oxide (NO) 9 and this, by triggering release of CGRP, 10 vasodilatation and nociceptor activation, provides a link between neuronal activity and vascular tone.
One consequence of the release of neuroactive substances is neurogenic inflammation, which is accompanied by vasodilatation, disruption of membrane barriers and plasma protein extravasation.
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Hypersensitisation of trigeminal nerve endings may underlie peripheral sensitisation and prolongation of migraine pain. Central sensitisation of the trigeminal system may also contribute to severe prolonged migraine headache pain -this also manifests itself as a return of pain on head movement or scalp pressure after attacks have subsided -and head allodynia. 6 The critical importance of central sensitisation is underlined by observations that triptans may be ineffective once allodynia is established. 12 well as obvious triggers (e.g., days of menstrual flow), can be extremely helpful in determining the need for preventive strategies and in the evaluation of therapeutic outcomes. 13 Another important factor is migraine-related disability and this can be assessed using the very pragmatic and useful Migraine Disability Assessment Score 14 or a similar approach. Together, these aspects help to determine the need for and choice of acute and preventive treatments. Traditionally, the management of migraine is divided into acute or symptomatic treatments and preventive strategies.
Patients look for faster onset of relief, more complete relief, no recurrent headache and no adverse events; therefore the goals of acute migraine treatment are to treat attacks rapidly and to prevent their recurrence with minimal or no adverse events, in order to restore the patient's ability to function. 15 To meet these objectives it is important to bear in mind some general principles: the importance of intervening early when the pain is still mild, the need for adequate doses and appropriate routes of administration, and the need for co-administration of antiemetic or prokinetic drugs to facilitate the absorption of the primary drug and guard against chronification of the condition and the development of medication-overuse headache. Indeed, the frequent use of some migraine medications can lead to medication-overuse headache. Both men and women using barbiturates or opiates are at increased risk of developing chronic migraine. 16 The critical levels of exposure to opiates and barbiturates are around eight and five days per month, respectively.
The use of non-steroidal anti-inflammatory drugs (NSAIDs) has been shown to reduce the risk of progression in patients with low to moderate progression risk (<10 days per month of headache) and to increase this risk in those with a critical headache frequency. Triptan use has also been found to increase the risk of progression in the critical risk group. 17, 18 These findings underline the need for vigilant monitoring of opiates and barbiturates, and also of NSAIDs associated with caffeine (if prescribed), and the need for close attention to the frequency of headaches. (demonstrated in clinical placebo-controlled studies), providing they are used at the recommended doses (see Table 1 ) and in the absence of contraindications, are: ASA, ibuprofen, diclofenac, metamizole, tolfenamic acid, naproxen sodium and ketoprofen. 22 Contraindications for the use of NSAIDs are peptic ulcer and haemorrhagic diathesis. Long-term side effects associated with ASA and other NSAIDs (especially gastric symptoms) are well documented.
However, in short-term trials ASA was generally well tolerated.
NSAIDs were consistently associated with lower overall adverse event rates when compared with ergotamine; in particular, lower rates of nausea and vomiting were noted.
Antiemetics or prokinetics (such as domperidone 10 mg orally and metoclopramide 10 mg orally or prochlorperazine 3 mg orally) are indicated in addition to analgesics or NSAIDs when treating attacks with severe nausea and vomiting (see Table 2 ). The oral combination of indomethacin, caffeine and prochlorperazine has been seen to have similar efficacy to oral sumatriptan Naproxen sodium 500-1,000
Ketoprofen 100
was superior to rectal sumatriptan. 24 Formulations containing NSAIDs (ASA or paracetamol) with metoclopramide are available in some countries, and paracetamol (1,000 mg) in association with metoclopramide (10 mg) is superior to placebo. [25] [26] [27] Furthermore, the combination of ASA or paracetamol with caffeine has been shown to be more effective than simple analgesics.
Specific Anti-migraine Drugs Ergot Derivatives
Ergotamine, introduced in 1926 by Maier, 28 was the first drug used for migraine attack treatment. In many countries it is the most widely used specific symptomatic migraine drug, probably because it is inexpensive and has a long duration of action. This drug is used in the treatment of long-lasting attacks with headache recurrence. However, ergotamine can no longer be considered the drug of choice as it carries a high risk of overuse, especially when combined with caffeine; indeed, the addition of caffeine enhances the absorption and possibly the vasoconstrictor action of ergotamine. The drug is associated with a high generalised vasoconstrictor effect if dosing is not carefully monitored.
Like the triptans, ergot derivatives exert an agonist action on serotonin Dihydroergotamine (DHE) is usually better tolerated than ergotamine but has poor oral bioavailability, which reduces its efficacy. Intranasal DHE has better bioavailability (about 40 %) but its onset of action is relatively slow and in two trials, in which it was compared with intranasal and subcutaneous sumatriptan, it was clearly shown to be inferior to the triptan. 29, 30 Parenteral DHE, i.e. an injectable, intravenous and subcutaneous solution, is more effective in severe migraine attacks but produces more side effects; 31 furthermore, in comparison with sumatriptan, it showed lower efficacy for the first two hours, even though it was apparently comparable thereafter. areas. 6 Although currently available in various formulations (tablets, nasal spray, subcutaneous injection, suppositories), most triptans are effective by the oral route of administration (see Table 3 ). Sumatriptan offers the most flexibility of formulation. If switching triptans fails to produce the desired effectiveness, the efficacy of treatment with these drugs could be improved by adding an NSAID. Such combination therapies produce more benefits than either monotherapy or placebo and also reduce headache recurrence, as shown in recent placebo-controlled trials of sumatriptan-naproxen sodium 36 and almotriptan-aceclofenac combinations. 37 The sumatriptan-naproxen sodium combination is moderately superior to sumatriptan or naproxen monotherapy 38 and theoretically able to abort migraine in its initial stages, i.e. at the level of the trigeminal ganglion, and prevent the slow central sensitisation phenomenon. 39 For headache recurrence, a second dose of the triptan is effective in most cases. 40 One of the most interesting products under development is a sumatriptan patch: NP101 is an iontophoretic patch that delivers sumatriptan transdermally (using a small electric current to drive the compound across the skin) and keeps its plasma levels above the target level of 10 ng/ml for longer than seven hours. 41 Transdermal iontophoretic delivery of sumatriptan via NP101 may offer significant clinical benefits for migraine patients, for example, circumventing the gastrointestinal disturbances, including nausea and gastric stasis, that are associated with migraine. The patch also provides consistent, predictable delivery of desired drug levels over a four-hour period.
This offers the potential to avoid atypical pain, pressure and other sensations commonly associated with current triptan formulations. 42 The combination of triptans with antiemetics is little studied, with only small studies indicating the benefits of this approach. Although one might expect this combination to be helpful, there is no clear clinical evidence that this is the case. receptors. The results of a Phase II trial were rather disappointing, in that NXN-188 failed to produce pain relief at two hours; however, statistically significant responses were obtained for pain freedom, sustained pain freedom and use of rescue medication. 57 Finally, there is also evidence of efficacy of a dopamine antagonist (intramuscular droperidol) 58 and a vanilloid receptor modulator (civamide) 59 in acute migraine pain.
Conclusion
The 
